Search stocks

Find any stock by ticker or company name

Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling

Finranks

Kompaniya

Biz haqimizda

Biz bilan bog'lanish

[email protected]

Bizni kuzating

Instagram
Telegram
LinkedIn

Barcha huquqlar himoyalangan.

Foydalanish shartlari

Bosh sahifa
Kuzatuv
Bozorlar
Kalendar
Skriner
Yangiliklar
Biz haqimizda

ACON - Aclarion, Inc. So'nggi Yangiliklar | Finranks

Home

/

ACON

A

Aclarion, Inc. (ACON)

NCM – Real vaqt narxi. Valyuta: USD

2.32

+0.04 (1.75%)

Bozor ochiq: Aug 12, 2026, 11:15 AM EDT

2.35

+0.07 (3.07%)

Oldingi bozordan keyin: Aug 11, 2026, 5:00 PM EDT

Umumiy
Yangiliklar
Grafik
Hisobotlar
Dividendlar
Kutilma
Egalik
Profil

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion, Inc. (ACON) Reports Q2 Loss, Lags Revenue Estimates

Aclarion, Inc. (ACON) came out with a quarterly loss of $1.12 per share versus the Zacks Consensus Estimate of a loss of $1.05. This compares to a loss of $2.75 per share a year ago.

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.

Videolar

No Data

There is no data to display

Press-relizlar

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Aclarion Receives Notice of Allowance for Patent Advancing Accuracy and Adoption of Nociscan's MR Spectroscopy (MRS) Scan Process

Patent protects the precision of MRS data capture within the target disc — a critical step in the Nociscan workflow Designed to reduce scan time, support faster technologist onboarding and deliver more reproducible results across imaging centers Extends Aclarion's IP protection to over 65 issued and pending patents worldwide, complementing its broader portfolio covering spectroscopy acquisition, data processing, biomarkers and analytics BROOMFIELD, Colo., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that the United States Patent and Trademark Office (“USPTO”) has issued a Notice of Allowance for U.S. Patent Application titled “Multi-Voxel Prescription for Lumbar Disc Evaluation.

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Aclarion Announces Nociscan® Now Available at Goodman Campbell Brain & Spine at Ascension St. Vincent, First Site in Indiana to Offer the Technology

Partnership brings Nociscan for chronic low back pain to one of the nation's leading neurosurgery and spine care networks Goodman Campbell Brain & Spine is recognized nationally for its role in neurosurgery training and clinical research Availability of Nociscan in Indiana reflects Company's focus on expansion and adding to its growing base of provider sites across the country BROOMFIELD, Colo., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company leveraging biomarkers and proprietary augmented intelligence (AI) algorithms to help physicians identify the location of chronic low back pain, today announced that its Nociscan platform is now available at Goodman Campbell Brain & Spine at Ascension St. Vincent, marking the first site in Indiana to offer the technology.